Takafira Mduluza Selected Research

Schistosomiasis haematobia (Schistosomiasis haematobium)

1/2022	Characterisation of tetraspanins from Schistosoma haematobium and evaluation of their potential as novel diagnostic markers.
11/2021	Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study.
1/2021	Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis.
1/2021	Effects of TNF-α and IL-10-819 T>C single nucleotide polymorphisms on urogenital schistosomiasis in preschool children in Zimbabwe.
1/2020	Interleukin-10 and tumour necrosis factor alpha promoter region polymorphisms and susceptibility to urogenital schistosomiasis in young Zimbabwean children living in Schistosoma haematobium endemic regions.
12/2019	Elevation of C-reactive protein, P-selectin and Resistin as potential inflammatory biomarkers of urogenital Schistosomiasis exposure in preschool children.
1/2017	Decrease in Seminal HIV-1 RNA Load After Praziquantel Treatment of Urogenital Schistosomiasis Coinfection in HIV-Positive Men-An Observational Study.
1/2016	Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and Primary School-Aged Children.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takafira Mduluza Research Topics

Disease

49	Infections 01/2023 - 02/2003
28	Schistosomiasis (Bilharziasis) 01/2023 - 09/2005
8	Schistosomiasis haematobia (Schistosomiasis haematobium) 01/2022 - 01/2016
6	Malaria 11/2016 - 09/2006
5	Reinfection 01/2021 - 01/2012
4	Inflammation (Inflammations) 01/2023 - 01/2016
4	Coinfection 01/2021 - 06/2011
3	COVID-19 02/2023 - 01/2021
3	Hypersensitivity (Allergy) 01/2021 - 04/2011
3	Necrosis 01/2021 - 01/2018
3	HIV Infections (HIV Infection) 09/2018 - 12/2014
2	Communicable Diseases (Infectious Diseases) 01/2022 - 01/2022
2	Neglected Diseases 01/2022 - 01/2021
2	Fibrosis (Cirrhosis) 01/2021 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2020
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 02/2023
1	Cognitive Dysfunction 01/2023
1	Rabies (Hydrophobia) 01/2022
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022
1	Dysbiosis 12/2021
1	Systemic Scleroderma (Systemic Sclerosis) 01/2021
1	Carcinogenesis 01/2021
1	Wounds and Injuries (Trauma) 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Proteinuria 01/2016
1	Albuminuria 01/2016
1	Dysuria 03/2015
1	Neoplasms (Cancer) 01/2015
1	Mannose-Binding Protein Deficiency 01/2015
1	Noncommunicable Diseases 01/2012

Drug/Important Bio-Agent (IBA)

20	Praziquantel (Biltricide)FDA Link 01/2022 - 08/2006
16	CytokinesIBA 01/2022 - 09/2006
13	AntigensIBA 01/2022 - 01/2005
11	Immunoglobulin G (IgG)IBA 01/2022 - 02/2003
11	AntibodiesIBA 11/2021 - 09/2006
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2012
7	Immunoglobulin E (IgE)IBA 01/2013 - 02/2003
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2005
6	VaccinesIBA 01/2022 - 07/2004
5	Peptides (Polypeptides)IBA 02/2023 - 01/2021
5	Interleukin-10 (Interleukin 10)IBA 01/2021 - 11/2007
4	InterleukinsIBA 01/2023 - 01/2018
4	Interleukin-4 (Interleukin 4)IBA 01/2022 - 11/2007
4	AllergensIBA 12/2021 - 04/2011
4	Interleukin-5 (Interleukin 5)IBA 07/2013 - 11/2007
3	C-Reactive ProteinIBA 01/2023 - 01/2012
3	Interleukin-6 (Interleukin 6)IBA 01/2023 - 07/2013
3	Indicators and Reagents (Reagents)IBA 01/2021 - 12/2009
3	Immunoglobulin M (IgM)IBA 12/2019 - 01/2005
3	Immunoglobulin A (IgA)IBA 09/2018 - 01/2005
2	Interleukin-17 (Interleukin 17)IBA 01/2023 - 01/2022
2	CarcinogensIBA 01/2022 - 01/2015
2	EnzymesIBA 01/2022 - 01/2021
2	EpitopesIBA 01/2022 - 04/2011
2	Interleukin-13IBA 01/2021 - 01/2018
2	ProteomeIBA 01/2021 - 01/2019
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 01/2020
2	ChitinasesIBA 01/2020 - 01/2012
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2023
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023
1	Recombinant ProteinsIBA 01/2023
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 01/2022
1	Cytochrome P-450 CYP3AIBA 01/2022
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	TetraspaninsIBA 01/2022
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	AutoantibodiesIBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	SolutionsIBA 01/2021
1	Subunit VaccinesIBA 01/2021
1	purineIBA 12/2020
1	Lactose FDA LinkGeneric 08/2020
1	Antinuclear AntibodiesIBA 01/2020
1	P-SelectinIBA 12/2019
1	ResistinIBA 12/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2018
1	Immunoglobulins (Immunoglobulin)IBA 09/2018
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Ointments (Pastes)IBA 01/2017
1	AntioxidantsIBA 01/2017
1	Lipoproteins (Lipoprotein)IBA 01/2016
1	LipidsIBA 01/2016
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 09/2015
1	AlbuminsIBA 03/2015
1	CreatinineIBA 03/2015
1	Codon (Codons)IBA 01/2015
1	Drinking WaterIBA 12/2014
1	interleukin-21 (interleukin 21)IBA 07/2013
1	Interleukin-23 (Interleukin 23)IBA 07/2013
1	Vitamin A (Retinol)FDA LinkGeneric 01/2012
1	Ferritins (Ferritin)IBA 01/2012
1	Vitamin D FDA LinkGeneric 01/2012
1	MicronutrientsIBA 01/2012

Therapy/Procedure

6	Aftercare (After-Treatment) 12/2020 - 08/2006
2	Mass Drug Administration 01/2020 - 01/2014
2	Drug Therapy (Chemotherapy) 03/2019 - 04/2017
1	Immunomodulation 01/2022
1	Art Therapy 01/2016